Bronchopulmonary dysplasia · preterm infants with or at risk of respiratory distress syndrome
Surfactant administration via thin catheter (S‐TC) probably leads to lower bronchopulmonary dysplasia (BPD) among survivors at 36 weeks'… compared with surfactant administration through an endotracheal tube (S‐ETT) (moderate certainty).
1 finding from 1 review
Death or survival with neurosensory disability ‐ not reported · preterm infants with or at risk of respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy
Carisbamate probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).
1 finding from 1 review
Seizure freedom · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes seizure freedom compared with placebo (very low certainty).
1 finding from 1 review
Treatment withdrawal · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal for any reason compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Participants who experienced any adverse event Adverse event regardless of severity · people with drug‐resistant focal epilepsy
Carisbamate showed no clear difference in proportion of participants who experienced atleast 1 adverse event compared with placebo (low certainty).
1 finding from 1 review
Dizziness · people with drug‐resistant focal epilepsy
It is very uncertain whether carisbamate changes adverse events: dizziness compared with placebo (very low certainty).
1 finding from 1 review
Drowsiness/somnolence (Event rate during treatment, length of treatment varied across trials) · people with drug‐resistant focal epilepsy
Carisbamate may leads to higher adverse events: somnolence compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality: 1‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 1‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
All‐cause mortality: 2‐year overall survival · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant S‐1 changes all‐cause mortality: 2‐year overall survival compared with gemcitabine (very low certainty).
1 finding from 1 review
Serious adverse events · people with resectable cholangiocarcinoma
1 finding from 1 review
FEV1 % predicted: relative change from baseline · adults and children with CF
1 finding from 1 review
Time to next exacerbation · adults and children with CF
1 finding from 1 review
Participants hospitalised for respiratory exacerbation · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in participants hospitalised for respiratory exacerbation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events (AEs) (1 or more events) · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).
1 finding from 1 review
All‐cause mortality · adults and children with CF
Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).
1 finding from 1 review
Erectile dysfunction · erectile dysfunction in men with obstructive sleep apnoea
2 findings from 1 review
Health‐related quality of life · erectile dysfunction in men with obstructive sleep apnoea
1 finding from 1 review
Minor adverse events · erectile dysfunction in men with obstructive sleep apnoea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found